Risperdal is a prescription antipsychotic that has been linked to abnormal breast growth in boys and men. Gynecomastia is a medical condition which can cause significant emotional trauma. Boys and men who developed male breasts while taking Risperdal have filed lawsuits nationwide against Janssen and Johnsons & Johnson, saying they were not adequately warned of the drug's risks. Johnson & Johnson resolved a federal lawsuit in 2013 when it agreed to pay $2.2 billion to the Department of Justice over allegations of fraud, the payment of kickbacks to physicians who prescribed Risperdal for uses that had not been FDA approved, and downplaying the Risperdal gynecomastia risk on the drug's label.
Risperdal (risperidone) is a drug commonly used in the United States to treat schizophrenia, Bipolar I Disorder, and autism. The drug treats these conditions by altering hormone levels in the body, which regulate traits commonly associate with one gender or the other. Risperdal works by raising the body's prolactin level, the hormone responsible for boosting the growth of breast tissue. Teenage boys and men who have taken Risperdal report developing large male breasts which must be surgically removed in some cases. There are no serious physical complications related to the growth of breast tissue in men and boys, but there are obvious psychological and emotional implications. In the face of Risperdal lawsuit allegations, Janssen officials have asserted that male breast growth is harmless. Teenage boys and men who have grown breasts as a result of Risperdal widely disagree, as do psychologists and other experts.
Risperdal is an anti-psychotic drug used to treat irritability related to austism as well as schizophrenia and Bipolar I disorder in children and adults. It is sold by Janssen, a subsidiary of Johnson & Johnson, and has been in use in the United States since 1993. The drug works by altering the body's natural hormone levels. While affective at treating the conditions for which it is approved, Risperdal has been found to cause abnormal swelling of breast tissue and even lactation in men and boys. Male breast growth can cause emotional trauma, social stigma, and mental anguish.
Multiple research teams have produced evidence linking Risperdal to heightened prolactin levels and abnormal male breast growth. An article in the Wall Street Journal quoted Dr. P. Murali Doraiswamy, the Duke psychiatrist who co-authored an FDA study on prolactin and antipsychotics as saying that Risperdal has been linked to a higher risk of male breast growth than any similar drug. This is just one of several pieces of medical research linking Risperdal to unwanted breast growth. Risperdal gynecomastia lawsuits assert the company knew of the risk of breast growth yet downplayed it in drug advertising in order to increase sales. In 2007, Risperdal reached record sales of $4.5 billion. Research shows that the rate at which males taking Risperdal experience breast growth is far higher than the 2.3% Janssen projected based on clinical testing.
Federal regulators have never issued an official warning regarding the risk of male breasts from Risperdal. This fact, in tandem with the drug maker's failure to issue a clear warning about the risk, has resulted in significant damage, say some experts. A warning issued by federal regulators brings the public's attention to a medical condition, and makes physicians take note of existing research. With no FDA warning on Risperdal breast growth, boys and men have taken the drug without knowledge of the threat. And when they do develop breast tissue, they are slower to come forward if they do not know the risk is widespread. Suffering their shame alone, men and boys who have grown breasts from Risperdal encounter significant mental anguish, according to psychologists.
Boys and men who have developed breasts while taking Risperdal may seek compensation for the medical expenses, damages, and mental anguish they have suffered as a result of the drug by filing a Risperdal lawsuit against Janssen and Johnson & Johnson. Risperdal lawsuits aim to hold the drug company accountable for its failure to adequately warn consumers of the known risks of Risperdal. Men and boys who have been harmed by Risperdal breast growth may be entitled to compensation as a result of the suffering, damages, and expenses they have sustained.
Attorneys handling Risperdal lawsuits are now accepting claims from boys, men, and the family members of males who have developed breasts while taking Risperdal. These individuals may be entitled to compensation for the damages, expenses and emotional anguish they have suffered as a result of taking Risperdal. The Onder Law Firm will represent all persons involved in a Risperdal male breast lawsuit on a contingency basis, meaning there are never any legal fees unless we win compensation in your case. For a free no-obligation consultation please complete the brief online contact form or call us at 1-800-799-2824 and one of our attorneys handling national* Risperdal lawsuits will contact you to answer any of your questions.
A leader in cancer research at Harvard University asserts that perhaps 10,000 cases of ovarian cancer can be blamed each year on perineal talc use in the US. Despite the existence of evidence that talc-based products are dangerous and can cause cancer, talc is not regulated in the US. The American Cancer Society estimates that in 2013, about 22,240 new cases of ovarian cancer will be diagnosed, while 14,030 women will die as a result of ovarian cancer in the US.
Roundup weed killer, manufactured by Monsanto, uses a chemical called glyphosate, which the World Health Organization labeled as a probable carcinogen in 2015. Roundup is the most popular of all glyphosate-based herbicides. As little as 8 hours of Roundup exposure has been linked to an increased risk of non-Hodgkin lymphoma, multiple myeloma, and leukemia. Millions of gardeners, landscapers, farmers and others have been exposed to Roundup cancer risks.
Physiomesh is a form of surgical mesh that has been used in hernia repair surgeries. Ethicon Physiomesh was used in ventral hernia repair and has been pulled from the market due to a high failure rate. Persons with Ethicon Physiomesh have experienced an array of complications that include pain, infection, hernia recurrence, adhesion or scar-tissue buildup, intestinal blockage, bleeding, perforation, organ damage, and the need for revision surgery.